Investors are particularly impressed with how the company has managed its product transitions. For years, the market worried that the decline of the blockbuster drug Humira would hurt the bottom line. However, the latest data shows that the plan to replace that revenue is working.The most immediate reason for the surge in options is the upcoming fourth-quarter 2025 earnings report. AbbVie is estimated to release these results on Feb. 4, 2026. Institutional confidence is high because the company has establis ...

AbbVie (NYSE:ABBV) FY Conference January 14, 2026 11:15 AM ET Company ParticipantsJeff Stewart - Chief Commercial OfficerScott Reents - CFORoopal Thakkar - EVPConference Call ParticipantsChris Schott - AnalystChris SchottGood morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this Fireside Chat today with AbbVie. From the company, we have Scott Reents, CFO, Jeff Stewart, Chief Commercial Officer, and Roopal Thakkar, Chief Medical Officer. So, happy New Year, guys, and thank ...